Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 394

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 14
Chunk 394
---
 of December 31, 2024 $215,243  $141,544                    As of December 31, 2024 and 2023 operating lease liabilities as follows:    As of   December 31,  December 31,   2024  2023 Balance as of beginning of the year $133,395  $56,775 Add: addition of lease liabilities (1)  145,736   113,279 Less: gross repayment  (56,598)  (39,798)Add: imputed interest (4)  11,795   5,613 Less: lease termination (3)  (25,679)  - Foreign translation differences  1,908   (2,474)Balance as of end of the year  210,557   133,395 Less: lease liabilities current portion  (50,816)  (34,632)Lease liabilities non-current portion $159,741  $98,763   

 F-19Table of Contents

BIONEXUS GENE LAB CORP.

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

As of December 31, 2024 and 2023, the maturities of the operating lease liabilities are as follows:   As of   December 31,  December 31,   2024  2023 Years ending December 31:      2024  -   43,213 2025  62,939   36,634 2026  62,311   36,634 2027  55,403   24,568 2028  45,166   14,332 2029  12,848   - Total undiscounted cash flows  238,667   155,381 Less: Interest imputed on lease liabilities  (28,110)  (21,986)Present value of lease liabilities  $210,557  $133,395  (1) During the year ended December 31, 2024,